Developing proteomic and epigenetic BIOmarkers to bring advanced RA Diagnostics and Treatment

Purpose and goal

There is a high need for better early diagnostics for chronic inflammatory diseases (CID) such as rheumatoid arthritis (RA). We are using proteomics and epigenetics to identify biomarkers associated with disease progression and treatment response in RA. The aim is to lay the foundation for a clinically useful test that can identify patients with the highest likelihood of a positive treatment response to Lipum´s drug candidate SOL-116 and improve the possibilities for personalized treatment.

Expected effects and result

Together with Age Labs AS, we intend to develop and commercialize the biomarker as a SOL-116 drug Companion Diagnostic Test (CDT). This test can guide doctors in choosing the right treatment for each patient. Patients will benefit from an effective treatment earlier in the disease course and thereby avoid no or low response to the treatment, side effects and disease progress. Moreover, the costs for healthcare and society will be reduced.

Planned approach and implementation

The consortium will conduct research to identify protein biomarkers associated with the target protein BSSL (Bile Salt-Stimulated Lipase) plasma levels and alterations in the plasma proteome associated with response to a treatment with SOL-116. Following that, the partners will conduct research to identify epigenetic changes associated with response to treatment with SOL-116 in RA patients, and how to combine this information with protein biomarkers in an optimal way for design of a CDT.